230 related articles for article (PubMed ID: 20534864)
1. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.
Magro M; Andreu D; Gómez-Puertas P; Melero JA; Palomo C
J Virol; 2010 Aug; 84(16):7970-82. PubMed ID: 20534864
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
Sastre P; Melero JA; García-Barreno B; Palomo C
Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
6. Water extract of Cinnamomum cassia Blume inhibited human respiratory syncytial virus by preventing viral attachment, internalization, and syncytium formation.
Yeh CF; Chang JS; Wang KC; Shieh DE; Chiang LC
J Ethnopharmacol; 2013 May; 147(2):321-6. PubMed ID: 23518419
[TBL] [Abstract][Full Text] [Related]
7. Structure and function of respiratory syncytial virus surface glycoproteins.
McLellan JS; Ray WC; Peeples ME
Curr Top Microbiol Immunol; 2013; 372():83-104. PubMed ID: 24362685
[TBL] [Abstract][Full Text] [Related]
8. Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.
Palomo C; Mas V; Detalle L; Depla E; Cano O; Vázquez M; Stortelers C; Melero JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6498-6509. PubMed ID: 27550346
[TBL] [Abstract][Full Text] [Related]
9. Virus neutralization assays for human respiratory syncytial virus using airway organoids.
van Dijk LLA; Rijsbergen LC; Rubio BT; Schmitz KS; Gommers L; Comvalius AD; Havelaar A; van Amerongen G; Schepp R; Lamers MM; GeurtsvanKessel CH; Haagmans BL; van Binnendijk R; de Swart RL; de Vries RD
Cell Mol Life Sci; 2024 Jun; 81(1):267. PubMed ID: 38884678
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
Leemans A; De Schryver M; Van der Gucht W; Heykers A; Pintelon I; Hotard AL; Moore ML; Melero JA; McLellan JS; Graham BS; Broadbent L; Power UF; Caljon G; Cos P; Maes L; Delputte P
J Virol; 2017 Jul; 91(14):. PubMed ID: 28468888
[TBL] [Abstract][Full Text] [Related]
11. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
Marsh R; Connor A; Gias E; Toms GL
J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
14. Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
Thakur N; Conceicao C; Isaacs A; Human S; Modhiran N; McLean RK; Pedrera M; Tan TK; Rijal P; Townsend A; Taylor G; Young PR; Watterson D; Chappell KJ; Graham SP; Bailey D
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33054904
[TBL] [Abstract][Full Text] [Related]
15. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
[TBL] [Abstract][Full Text] [Related]
16. Xiao-Qing-Long-Tang (Sho-seiryu-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract.
Chang JS; Yeh CF; Wang KC; Shieh DE; Yen MH; Chiang LC
J Ethnopharmacol; 2013 May; 147(2):481-7. PubMed ID: 23542148
[TBL] [Abstract][Full Text] [Related]
17. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.
Bottom-Tanzer SF; Rybkina K; Bell JN; Alabi CA; Mathieu C; Lu M; Biswas S; Vasquez M; Porotto M; Melero JA; Más V; Moscona A
mBio; 2019 Feb; 10(1):. PubMed ID: 30782664
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System.
Haid S; Grethe C; Bankwitz D; Grunwald T; Pietschmann T
J Virol; 2015 Dec; 90(6):3065-73. PubMed ID: 26719246
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
